- STAAR Surgical (STAA, Financial) to release Q1 2025 earnings on May 7, 2025.
- The company has sold over 3 million ICLs globally.
- STAAR Surgical dominates the phakic IOL market with its EVO ICL™ product line.
STAAR Surgical Company (STAA), a leader in the development of phakic intraocular lenses, has announced it will release its financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after the market closes. Investors and stakeholders are invited to join an earnings conference call and webcast at 5:15 p.m. ET the same day to discuss the company’s financial performance and business developments. The live webcast can be accessed through the STAAR website or a direct link provided for the event.
Founded in 1982, STAAR Surgical has been at the forefront of ophthalmic surgery innovations, specifically through its EVO ICL™ family of Implantable Collamer® Lenses. These lenses offer a minimally invasive solution for vision correction, allowing users to reduce or eliminate dependence on glasses or contact lenses. The EVO ICL™ significantly enhances visual freedom and convenience, with over 3 million units sold in more than 75 countries.
Headquartered in Lake Forest, California, STAAR operates research, development, manufacturing, and packaging facilities in both California and Switzerland, focusing exclusively on ophthalmic surgical solutions. For more detailed information about their products and corporate updates, stakeholders can visit their official website at investors.staar.com, where they also provide email alert services for the latest company news.
